Financial Engines Advisors L.L.C. Sells 175 Shares of Eli Lilly and Company (NYSE:LLY)

Financial Engines Advisors L.L.C. lowered its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 10.6% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,474 shares of the company’s stock after selling 175 shares during the quarter. Financial Engines Advisors L.L.C.’s holdings in Eli Lilly and Company were worth $1,138,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Financial Counselors Inc. increased its stake in shares of Eli Lilly and Company by 3.7% in the 4th quarter. Financial Counselors Inc. now owns 50,599 shares of the company’s stock worth $39,062,000 after purchasing an additional 1,806 shares in the last quarter. Penobscot Investment Management Company Inc. grew its holdings in Eli Lilly and Company by 17.2% during the fourth quarter. Penobscot Investment Management Company Inc. now owns 9,173 shares of the company’s stock valued at $7,082,000 after purchasing an additional 1,343 shares during the period. Morey & Quinn Wealth Partners LLC purchased a new stake in Eli Lilly and Company in the fourth quarter worth about $400,000. Trust Investment Advisors lifted its position in shares of Eli Lilly and Company by 1.5% during the 4th quarter. Trust Investment Advisors now owns 21,388 shares of the company’s stock valued at $16,511,000 after buying an additional 311 shares in the last quarter. Finally, Murphy & Mullick Capital Management Corp purchased a new position in shares of Eli Lilly and Company during the 4th quarter valued at about $1,264,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 3.0 %

Shares of NYSE:LLY opened at $826.84 on Thursday. The company has a market cap of $783.98 billion, a price-to-earnings ratio of 70.61, a PEG ratio of 1.40 and a beta of 0.34. Eli Lilly and Company has a 12 month low of $711.40 and a 12 month high of $972.53. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. The company has a 50-day moving average price of $841.16 and a 200 day moving average price of $837.54.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. As a group, equities research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company declared that its Board of Directors has approved a stock buyback plan on Monday, December 9th that allows the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization allows the company to buy up to 2% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s leadership believes its stock is undervalued.

Insider Activity

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the business’s stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the transaction, the chief accounting officer now owns 5,840 shares in the company, valued at $4,778,521.60. The trade was a 14.62 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 0.13% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on LLY. Leerink Partners set a $950.00 target price on shares of Eli Lilly and Company in a research note on Friday, January 17th. Berenberg Bank set a $970.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, January 16th. Morgan Stanley set a $1,146.00 target price on shares of Eli Lilly and Company in a research note on Thursday, March 6th. Bank of America reiterated a “buy” rating and issued a $997.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, December 10th. Finally, Truist Financial boosted their price objective on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a research report on Monday, February 3rd. Three equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $1,009.72.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.